Framework

V3 + DiMe

Verification · analytical · clinical

Documentation

End-to-end

Methods, evidence, version history

Submission

Supported

IND · IDE · NDA · BLA · MAA · PMCF

Built for regulatory review, not just data collection

Regulatory Alignment
for Digital Endpoints

Regulatory alignment is more than a checklist. It is the discipline of building validation, documentation, and provenance into a digital-endpoint program from day one — so the data your statistical and regulatory teams hand to reviewers is defensible, reproducible, and aligned with current FDA, EMA, and DiMe practice.

FDA / EMA aligned · V3 framework · Submission-ready

FDA
EMA
V3
DiMe

Regulatory Alignment Workflow

Define → Validate → Document → Defend

Will the regulator accept our digital endpoint?
Acceptance comes from method, not from the device. Delve's V3-aligned package gives reviewers the verification, validation, and provenance they expect to see.
Method first. Metric second. That's how the conversation stays on the science.
Defensible by design Methods + evidence + provenance

What Regulatory Alignment Really Means

In clinical research, regulatory alignment for a digital endpoint program is the work that makes the program defensible — to reviewers, auditors, and statistical teams. It is not a one-time review at filing. It is the discipline of building documentation, validation evidence, and provenance into the operating model from the beginning.

Regulatory alignment is a property of the documentation and the operating model — not of the device.

Related pages: Regulatory-Ready Endpoints · Validation

Digital endpoint pipeline aligned with FDA/EMA regulatory practice

Why Regulatory Submissions Stall

Most digital endpoint submissions stall not because the underlying technology is unsound, but because the validation evidence is missing, partial, or not packaged in a reviewable way.

Black-box algorithms

Reviewers can't accept a metric they can't explain. Opaque vendor algorithms are a hard stop.

Validation gaps

Verification done; analytical validation thin; clinical validation absent. Submissions need all three.

No version history

An algorithm that changes silently mid-study leaves reviewers unable to trust comparisons over time.

Provenance loss

Values arriving without device, firmware, and algorithm-version context can't be re-analyzed.

Endpoint-intent mismatch

Strong validation against the wrong clinical question doesn't help the submission.

Late documentation

Documentation written after the trial is harder to defend than documentation built alongside it.

Regulatory alignment is something you build in from the beginning — not bolt on at filing time.

Delve Regulatory Approach vs Traditional Wearable Programs

Traditional wearable program

  • Vendor-defined algorithms
  • Patchy validation evidence
  • Algorithm history not tracked
  • Documentation assembled at filing time
  • Provenance not preserved

Delve regulatory-aligned approach

  • Documented, versioned algorithms
  • V3-aligned verification + analytical + clinical validation
  • Change history maintained over the study lifetime
  • Documentation built alongside the trial
  • Provenance preserved with every value

We don't replace your regulatory team — we give them an organized, defensible package to file.

What a Regulatory-Aligned Program Includes

Programs that hold up under regulatory review are organized for review — not just for data collection.

When the package is organized, the conversation with reviewers stays focused on the science.

See related pages: Security & Privacy · Validation · Endpoint APIs

Regulatory-aligned digital endpoint program with validation evidence and version history

Aligned With Current Regulatory Practice

Delve tracks the frameworks reviewers actually use — and updates validation patterns as those frameworks evolve.

FDA Digital Health CoE

Methodology aligned with current FDA guidance for digital health technologies in clinical trials.

EMA qualification advice

Endpoint methods take EMA qualification opinions and scientific advice into account.

DiMe V3 framework

Verification, analytical, and clinical validation patterns follow the Digital Medicine Society V3 framework.

21 CFR Part 11

Electronic records and signatures handled in 21 CFR Part 11-compliant infrastructure.

GCP

Endpoint operations follow ICH GCP principles for clinical investigation.

Audit support

Immutable audit trail, scoped access, and documented procedures for inspections.

We support — we don't replace — your regulatory team. The submission still belongs to your filers.

FAQ

Will the FDA / EMA accept this digital endpoint?

Acceptance is decided per submission. What Delve provides is a documented, defensible package containing the evidence reviewers ask for. Your regulatory team owns the submission strategy.

How is this different from 'validated' consumer wearables?

Consumer 'validation' typically refers to the sensor. Regulatory-aligned endpoints require validation of the full chain — sensor, algorithm, clinical interpretation — documented in a way reviewers can audit.

Can Delve attend regulatory meetings with us?

Yes. We'll join pre-submission meetings or sponsor briefings to walk through the digital endpoint package if that helps your regulatory team.

Build Digital Endpoints That Survive Review

Delve develops digital endpoints with the documentation, validation, and version control your submission teams need from day one — across pivotal, post-market, and real-world programs.

Book a Regulatory Discussion

Explore Delve for Pharma →